Results 151 to 160 of about 9,362 (182)

Pilot Assessment of RNA Stabilization Methods for Influenza A Virus in Swine Oral Fluids. [PDF]

Pathogens
Munguía-Ramírez B, Armenta-Leyva B, Giménez-Lirola L, Zhang Y, Arruda B, Ciacci-Zanella G, Zimmerman J.   +6 more
europepmc   +1 more source

Extended influenza seasons in Australia and New Zealand in 2025 due to the emergence of influenza A(H3N2) subclade K viruses. [PDF]

Euro Surveill
Dapat C, Peck H, Jelley L, Diefenbach-Elstob T, Slater T, Hussain S, Britton P, Cheng AC, Wood T, Howard-Jones A, Deng YM, Miller JE, Huang QS, Barr IG.   +13 more
europepmc   +1 more source

Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018. [PDF]

Emerg Infect Dis
Gray GC, Vlasova AN, Lednicky JA, Nguyen-Tien T, Shittu I, Li F.   +5 more
europepmc   +1 more source

Swine Influenza Viruses – Evolution and Zoonotic Potential [PDF]

, 2014
Fobian, Kristina
core  

Impact of maternal antibodies and weaning stress on the replication and transmission of human H3N2 influenza A in piglets. [PDF]

J Virol
Ciacci Zanella G, Cardenas MI, Hutter CR, Snyder CA, Wymore Brand M, Arruda B, Perez DR, Anderson TK, Rajão DS, Baker AL.   +9 more
europepmc   +1 more source

High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains. [PDF]

Elife
Kikawa C, Loes AN, Huddleston J, Figgins MD, Steinberg P, Griffiths T, Drapeau EM, Peck H, Barr I, Englund JA, Hensley SE, Bedford T, Bloom JD.   +12 more
europepmc   +1 more source

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. [PDF]

Vaccines (Basel)
Yoon Y, Cho HK, Kim KH, Park SE, Kim YJ, Lee J, Kim HM, Kim NH, Jo DS, Cho EY, Shin SH, Kim JH, Ryu JH, Park HK, Lee Y, Kim YK.   +15 more
europepmc   +1 more source

A live-attenuated influenza vaccine for H3N2 canine influenza virus

Virology, 2017
Canine influenza is a contagious respiratory disease in dogs caused by two subtypes (H3N2 and H3N8) of canine influenza virus (CIV). Currently, only inactivated influenza vaccines (IIVs) are available for the prevention of CIVs. Historically, live-attenuated influenza vaccines (LAIVs) have been shown to produce better immunogenicity and protection ...
Aitor Nogales, David J Topham, Pablo R Murcia   +2 more
exaly   +3 more sources

Virus-like particle vaccine protects against H3N2 canine influenza virus in dog [PDF]

Vaccine, 2013
In the present study, virus-like particles (VLPs) were evaluated as a candidate veterinary vaccine against canine influenza virus (CIV) subtype H3N2. Specific pathogen-free (SPF) beagle dogs received a single injection of a VLP vaccine containing hemagglutinin (HA) and M1 protein of CIV H3N2 (H3 HA VLP). The vaccine was tested at 3 different doses with
Dong-Hun Lee, Jae-Keun Park, Jung-Hoon Kwon   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Cellular microRNAs influence replication of H3N2 canine influenza virus in infected cells

Veterinary Microbiology, 2021
MicroRNAs (miRNAs) are known to play important regulatory roles in host-virus interactions. Avian-origin H3N2 canine influenza virus (CIV) has emerged as the most prevalent subtype among dogs in Asia since 2007. To evaluate the roles of host miRNAs in H3N2 CIV infection, here, miRNA profiles obtained from primary canine bronchiolar epithelial cells ...
Xing Xie, Maoda Pang, Yanbing Zhao
exaly   +3 more sources